{"id":6229,"date":"2019-10-22T15:57:19","date_gmt":"2019-10-22T10:27:19","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=6229"},"modified":"2021-07-24T12:57:35","modified_gmt":"2021-07-24T07:27:35","slug":"recent-pharma-happenings-for-gsk-az-vertex-bavarian-nordic","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-gsk-az-vertex-bavarian-nordic","title":{"rendered":"\ufeffFDA approval to AZ\u2019s Farxiga for heart failure; GSK divests two travel vaccines to Bavarian Nordic; New breakthrough therapy for Cystic Fibrosis"},"content":{"rendered":"\n

The US FDA today has given its\nnod to Trikafta (elexacaftor\/ivacaftor\/tezacaftor) of Vertex Pharmaceuticals, the\nfirst of its kind triple combination therapy for the patients with cystic fibrosis.\n<\/strong><\/h4>\n\n\n\n

The drug, Trikafta, has been\napproved for patients of age 12 years and older who have at least one F508del\nmutation in CFTR (cystic fibrosis transmembrane conductance regulator) gene, which\nmostly affects 90% of all the cystic fibrosis population. <\/p>\n\n\n\n

Cystic fibrosis can be a result of more than 1000 possible mutations in the CFTR gene that hampers the pathway of chloride channels which disrupts the traverse of chlorine ions and water molecules across cell membranes. The deletion of 3 bases in the CFTR gene is the most common type of mutation in Cystic fibrosis. <\/p>\n\n\n\n

Cystic fibrosis is a rare, progressive,\ngenetic disease known to affect more than 30,000 people in the US, as per Cystic\nFibrosis Foundation Patient Registry estimates. <\/p>\n\n\n\n

The Cystic fibrosis therapeutics market is mainly comprised of the following type of therapies: Mucolytics, Bronchodilators, Antibiotics, and CFTR Modulator therapies. Mucus thinners or mucolytics are medications that cause thinning of the mucus thereby making it easier to cough it out of lungs. <\/p>\n\n\n\n

In January 2012, ivacaftor<\/strong> (Kalydeco) was approved by the FDA as the first drug that treats the underlying cause of Cystic Fibrosis<\/a> (CF). Kalydeco represents a major advance in the treatment of Cystic Fibrosis for people with a specific type of this disease.<\/p>\n\n\n\n

Vertex Pharmaceuticals<\/a> has also developed a combination therapy of lumacaftor\/ivacaftor (Orkambi) which is used to treat patients carrying two copies of F508del mutations. Symdeko (tezacaftor\/ivacaftor) is also one of the Cystic fibrosis treatment options developed by the same company. <\/p>\n\n\n\n

Key players other than Vertex Pharmaceutical which are involved in developing Cystic fibrosis therapies<\/a> are Laurent Pharmaceuticals, Verona Pharma, Novoteris, Aridis Pharmaceuticals Eloxx Pharmaceutical and many others.<\/p>\n\n\n\n

GlaxoSmithKline has recently\nannounced to off-load two of its travel vaccines to Bavarian Nordic in an upfront\npayment of USD 336 Million. <\/strong><\/h4>\n\n\n\n

The agreement entitles Bavarian\nNordic to solely acquire worldwide manufacturing rights over Rabipur \/ RabAvert\nand Encepur. Moreover, GSK will also receive milestone payments and will\ncontinue to manufacture the vaccines until Bavarian Nordic becomes technologically\nenabled. <\/p>\n\n\n\n

Rabipur is a vaccine containing inactivated rabies virus given to people who are at risk of developing rabies. It also is equally effective if administered immediately after the animal bite suspected to have rabies. On the other hand, Encepur is a vaccine designed against tick-borne encephalitis<\/a> for people of age above 12 years.  <\/p>\n\n\n\n

According to the GSK\u2019s annual report, every day around 770 million vaccine doses is administered. The annual turnover of the company last year due to their vaccine segment was around USD 5.9 Million.<\/p>\n\n\n\n

AstraZeneca has announced the\nFDA recommendation for its Farxiga (dapagliflozin) as it can reduce the risk of\nhospitalization due to heart failure. <\/strong><\/h4>\n\n\n\n

The approval is based on the basis of results of the trial DECLARE-TIMI 58 CV whose subjects were the patients suffering from Type-2 Diabetes and established cardiovascular disease or multiple cardiovascular <\/a>risks. <\/p>\n\n\n\n

Earlier, the therapy was in the market indicated as monotherapy and combination therapy to lower down the blood sugar level. <\/p>\n\n\n\n

According to the CDC, more than 30 million people are living with diabetes and around 90% of them have type 2 diabetes. Moreover, an estimated number of 24.8 people per 100,000 died due to diabetes-related causes. <\/p>\n","protected":false},"excerpt":{"rendered":"

The US FDA today has given its nod to Trikafta (elexacaftor\/ivacaftor\/tezacaftor) of Vertex Pharmaceuticals, the first of its kind triple combination therapy for the patients with cystic fibrosis. The drug, Trikafta, has been approved for patients of age 12 years and older who have at least one F508del mutation in CFTR (cystic fibrosis transmembrane conductance […]<\/p>\n","protected":false},"author":1,"featured_media":6231,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[195,1271,704,903,349,639,5789],"industry":[17225],"therapeutic_areas":[17242,17243],"class_list":["post-6229","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-cystic-fibrosis","tag-delveinsight-pharma-news","tag-fda","tag-gsk","tag-latest-pharma-news","tag-pharma-news","tag-recent-pharma-news","industry-pharmaceutical","therapeutic_areas-cardiovascular-diseases","therapeutic_areas-respiratory-diseases"],"acf":[],"yoast_head":"\n\ufeffFDA approves Farxiga; GSK divests; New breakthrough therapy<\/title>\n<meta name=\"description\" content=\"The US FDA today has given its nod to Trikafta of Vertex Pharmaceuticals, triple combination therapy for the patients with cystic fibrosis.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-gsk-az-vertex-bavarian-nordic\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"\ufeffFDA approves Farxiga; GSK divests; New breakthrough therapy\" \/>\n<meta property=\"og:description\" content=\"The US FDA today has given its nod to Trikafta of Vertex Pharmaceuticals, triple combination therapy for the patients with cystic fibrosis.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-gsk-az-vertex-bavarian-nordic\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2019-10-22T10:27:19+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:27:35+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/10\/09022453\/22.10.2019_news.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"\ufeffFDA approves Farxiga; GSK divests; New breakthrough therapy","description":"The US FDA today has given its nod to Trikafta of Vertex Pharmaceuticals, triple combination therapy for the patients with cystic fibrosis.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-gsk-az-vertex-bavarian-nordic","og_locale":"en_US","og_type":"article","og_title":"\ufeffFDA approves Farxiga; GSK divests; New breakthrough therapy","og_description":"The US FDA today has given its nod to Trikafta of Vertex Pharmaceuticals, triple combination therapy for the patients with cystic fibrosis.","og_url":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-gsk-az-vertex-bavarian-nordic","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2019-10-22T10:27:19+00:00","article_modified_time":"2021-07-24T07:27:35+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/10\/09022453\/22.10.2019_news.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-gsk-az-vertex-bavarian-nordic","url":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-gsk-az-vertex-bavarian-nordic","name":"\ufeffFDA approves Farxiga; GSK divests; New breakthrough therapy","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-gsk-az-vertex-bavarian-nordic#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-gsk-az-vertex-bavarian-nordic#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/10\/09022453\/22.10.2019_news.jpg","datePublished":"2019-10-22T10:27:19+00:00","dateModified":"2021-07-24T07:27:35+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"The US FDA today has given its nod to Trikafta of Vertex Pharmaceuticals, triple combination therapy for the patients with cystic fibrosis.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-gsk-az-vertex-bavarian-nordic"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-gsk-az-vertex-bavarian-nordic#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/10\/09022453\/22.10.2019_news.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/10\/09022453\/22.10.2019_news.jpg","width":772,"height":482,"caption":"Pharma news"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/10\/09022453\/22.10.2019_news-300x187.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">cystic fibrosis<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">delveinsight pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">FDA<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">GSK<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Latest pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">recent pharma news<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">cystic fibrosis<\/span>","<span class=\"advgb-post-tax-term\">delveinsight pharma news<\/span>","<span class=\"advgb-post-tax-term\">FDA<\/span>","<span class=\"advgb-post-tax-term\">GSK<\/span>","<span class=\"advgb-post-tax-term\">Latest pharma news<\/span>","<span class=\"advgb-post-tax-term\">pharma news<\/span>","<span class=\"advgb-post-tax-term\">recent pharma news<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 7 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on Oct 22, 2019","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on Oct 22, 2019 3:57 pm","modified":"Updated on Jul 24, 2021 12:57 pm"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/6229","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=6229"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/6229\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/6231"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=6229"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=6229"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=6229"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=6229"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=6229"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}